Based on the Aerovate Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Aerovate Therapeutics Inc is USD 29.50 over the next 12 months. Aerovate Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aerovate Therapeutics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aerovate Therapeutics Inc’s stock price was USD 2.20. Aerovate Therapeutics Inc’s stock price has changed by -6.78% over the past week, +16.40% over the past month and -80.05% over the last year.
No recent analyst target price found for Aerovate Therapeutics Inc
No recent average analyst rating found for Aerovate Therapeutics Inc
Company Overview Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address: 930 Winter Street, Waltham, MA, United States, 02451 Read Less
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pu...Read More
Frequently Asked Questions About Aerovate Therapeutics Inc (AVTE) Stock
Based on ratings from 5 analysts Aerovate Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AVTE's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for AVTE is USD 29.50 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 2.
AVTE stock's Price/Earning ratio is 0.88.
Our analysis grades AVTE stock's Price / Earning ratio at C-. This means that AVTE stock's Price/Earning ratio is above 30% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AVTE may be undervalued for its sector.
The last closing price of AVTE's stock was USD 2.20.
The most recent market capitalization for AVTE is USD 0.06B.
Based on targets from 5 analysts, the average taret price for AVTE is projected at USD 29.50 over the next 12 months.
This means that AVTE's stock price may go up by +1,240.91% over the next 12 months.
We can't find any ETFs which contains Aerovate Therapeutics Inc's stock.
As per our most recent records Aerovate Therapeutics Inc has 51 Employees.
Aerovate Therapeutics Inc's registered address is 930 Winter Street, Waltham, MA, United States, 02451.
You can get more information about it from Aerovate Therapeutics Inc's website at https://aerovatetx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Aerovate Therapeutics Inc (AVTE) Stock
Based on ratings from 5 analysts Aerovate Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AVTE's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for AVTE is USD 29.50 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 2.
AVTE stock's Price/Earning ratio is 0.88.
Our analysis grades AVTE stock's Price / Earning ratio at C-. This means that AVTE stock's Price/Earning ratio is above 30% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AVTE may be undervalued for its sector.
The last closing price of AVTE's stock was USD 2.20.
The most recent market capitalization for AVTE is USD 0.06B.
Based on targets from 5 analysts, the average taret price for AVTE is projected at USD 29.50 over the next 12 months.
This means that AVTE's stock price may go up by +1,240.91% over the next 12 months.
We can't find any ETFs which contains Aerovate Therapeutics Inc's stock.
As per our most recent records Aerovate Therapeutics Inc has 51 Employees.
Aerovate Therapeutics Inc's registered address is 930 Winter Street, Waltham, MA, United States, 02451.
You can get more information about it from Aerovate Therapeutics Inc's website at https://aerovatetx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVTE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
